Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2003
04/19/2003CA2408797A1 Treatment of breast cancer
04/17/2003WO2003031940A2 Structural and cytoskeleton-associated proteins
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031595A2 Molecules for disease detection and treatment
04/17/2003WO2003031584A2 Axon repair
04/17/2003WO2003031568A2 Intracellular signaling molecules
04/17/2003WO2003031477A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
04/17/2003WO2003031473A1 Leukocyte inactivation module
04/17/2003WO2003031462A2 Nogo receptor-mediated blockade of axonal growth
04/17/2003WO2003031448A1 Reverse-turn mimetics and method relating thereto
04/17/2003WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003WO2003031416A2 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
04/17/2003WO2003031415A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
04/17/2003WO2003031412A1 Piperidine compounds as muscarinic antagonists
04/17/2003WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
04/17/2003WO2003030947A2 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030943A1 Compositions comprising hydroxyapatite useful for the administration of therapeutic agents
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030939A1 Therapies for treating respiratory diseases
04/17/2003WO2003030935A2 Adjuvants for nucleic acid vaccines
04/17/2003WO2003030934A2 Cpg formulations and related methods
04/17/2003WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
04/17/2003WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
04/17/2003WO2003030910A1 Pharmaceutical composition for the treatment of disorders of non-human mammals
04/17/2003WO2003030908A2 Inhibitors of the egf receptor for the treatment of thyroid cancer
04/17/2003WO2003030906A1 Treating infections by administration of oxazolidinones to the skin
04/17/2003WO2003030902A1 Imidazole derivates as anti-inflammatory agents
04/17/2003WO2003030893A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
04/17/2003WO2003030892A1 Methods for treating dry eye
04/17/2003WO2003030886A2 Allylamides useful in the treatment of alzheimer's disease
04/17/2003WO2003030883A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
04/17/2003WO2003030870A1 Prolonged release biodegradable microspheres and method for preparing same
04/17/2003WO2003030833A2 Angiopoietin-2 specific binding agents
04/17/2003WO2003030832A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030824A2 Methods and compositions for treating dermal lesions
04/17/2003WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders
04/17/2003WO2003030813A2 Anti-irritating rosacea treatment
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003030612A2 Methods for modulating activity of the fxr nuclear receptor
04/17/2003WO2003020259A3 Combinations of dmxaa and other anti-cancer agents
04/17/2003WO2003017927A3 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
04/17/2003WO2002096903A3 Chemical derivatives and the use thereof as an anti-telomerase agent
04/17/2003WO2002089770A3 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
04/17/2003WO2002085943A3 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
04/17/2003WO2002083727A3 Nucleic acid sequences of hyperplasies and tumors of the thyroid
04/17/2003WO2002078620A3 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
04/17/2003WO2002076486A3 Histidine-rich glycoprotein
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002069968A8 New use
04/17/2003WO2002069943A3 Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies
04/17/2003WO2002058694A9 Method of treating hematologic tumors and cancers using beta lapachone
04/17/2003WO2002058684A3 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
04/17/2003WO2002051237A9 Helicobacter proteins, nucleic acids and uses thereof
04/17/2003WO2002050284A3 Oxidoreductases
04/17/2003WO2002041871A3 Composition comprising an imexon or derivatives thereof and lipids
04/17/2003WO2002032960A3 Methods of selecting compounds for modulation of bladder function
04/17/2003WO2002032445A3 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018576A3 Compositions and methods relating to lung specific genes
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2002010402A3 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides
04/17/2003WO2001078709A3 Treatment of neurodegenerative disease
04/17/2003WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
04/17/2003WO2001072773A3 Genes isolated from dendritic cells, gene products and methods employing the same
04/17/2003WO2000002548A3 Inhibitors of proteasomal activity for stimulating bone and hair growth
04/17/2003US20030074223 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
04/17/2003US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
04/17/2003US20030073833 Antiinflammatory agents; anticoagulants
04/17/2003US20030073745 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
04/17/2003US20030073741 Using N-benzylindolenyacetimide
04/17/2003US20030073739 Novel arginine/ascorbic acid mixed powder as an oral supplement
04/17/2003US20030073738 Synergistic mixture; anticancer, antitumor agents
04/17/2003US20030073737 Tolerance induction
04/17/2003US20030073729 Medicaments for diabetic complication and neuropathy, and uses thereof
04/17/2003US20030073728 Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
04/17/2003US20030073719 Chiral salt resolution
04/17/2003US20030073715 Nasal administering; side effect reduction
04/17/2003US20030073714 Prevent drug abruse; side effect reduction; administering mixture of opioid antagonist, releasable form and sequestering agent
04/17/2003US20030073713 Inhibitors of ABC drug transporters at the blood-brain barrier
04/17/2003US20030073705 Method of treatment
04/17/2003US20030073690 Controlling pain in mammals
04/17/2003US20030073688 Novel substituted benzoxazines as integrin antagonists
04/17/2003US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents
04/17/2003US20030073677 Synergistic mixtures; anticancer agents; 2-(2 -methyl-4-thiazolyl)ethenyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9 -dione or 4-aza-17-oxabicyclo(14.1.0) heptadecane-5,9-dione or 1-aza-13-cyclohexadecene-2,6-dione or 1-oxa-13-cyclohexadecene-2,6-dione derivatives
04/17/2003US20030073673 Hormonal contraceptive product
04/17/2003US20030073656 Using a tyrosine kinase receptor inhibitor
04/17/2003US20030073651 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
04/17/2003US20030073646 Synergistic mixture containing bactericide, fungicide and nitroindazole
04/17/2003US20030073645 Synergistic mixture; antidiabetic agents
04/17/2003US20030073644 Combinations comprising a beta-agonist and a further antidiabetic agent
04/17/2003US20030073628 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
04/17/2003US20030073619 Branched polyethylenimine
04/17/2003US20030073614 Methods for affecting various diseases utilizing LXR compounds
04/17/2003US20030073611 Detoxification of cells, tissues
04/17/2003US20030073610 Prevention protein misfolding; central nervous system disorders; Alzheimer's, Parkinson's, Huntington's disease therapy
04/17/2003US20030073609 Enhanced pharmacokinetic profile of intradermally delivered substances
1 ... 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 ... 1151